3 completed, 3 terminated. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow reldesemtiv: new trials by email Literature Review of reldesemtiv trials Research Report on reldesemtiv
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) Reldesemtiv - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 71 | 2022-08-04 | 2024-08-13 |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Reldesemtiv, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 489 | 2021-08-16 | 2024-12-05 |
| A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) Reldesemtiv, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Cytokinetics | 458 | 2017-07-24 | 2020-09-11 |
| A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility reldesemtiv, Placebo - Mobility Limitation | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 42 | 2017-06-28 | 2024-10-31 |
| A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease Reldesemtiv, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 46 | 2016-06-30 | 2024-11-14 |
| A Study of CK-2127107 in Patients With Spinal Muscular Atrophy Placebo, Reldesemtiv 150 mg, Reldesemtiv 450 mg - Spinal Muscular Atrophy | Phase 2 | Completed | Cytokinetics | 70 | 2016-01-14 | 2020-08-31 |
Amyotrophic Lateral Sclerosis (3) · Mobility Limitation (1) · Muscular Atrophy, Spinal (1) · Pulmonary Disease, Chronic Obstructive (1)
Cytokinetics (4) · Astellas Pharma Global Development, Inc. (2)
United States (6) · Canada (4) · Australia (3) · Ireland (3) · Netherlands (3) · Spain (3) · Belgium (2) · Italy (2) · Sweden (2) · Denmark (1) · France (1) · Germany (1) · Poland (1) · Portugal (1) · Switzerland (1)
MD Cytokinetics (1)
PMID 37254449, PMID 31081694, PMID 32969758, PMID 34218726, PMID 36503310, PMID 37641579, PMID 40126464, PMID 40503807, PMID 40576049, PMID 41121745, PMID 41553108